23 Mar 2011

DR-TB drugs under the microscope

Tags: Access Campaign, Diseases, DNDi, Report, Tuberculosis, World TB Day

Treating DR-TB is complicated from a programmatic perspective: treatment is individualised, tailored according to which drugs a patient is resistant to. It is long and taxing, requiring people to take a course of antibiotics for up to two years and endure often intolerable side effects.

 

 

DR-TB_drugs_under_the_microscope.pdf

 

Treating DR-TB is complicated from a programmatic perspective: treatment is individualised, tailored according to which drugs a patient is resistant to. It is long and taxing, requiring people to take a course of antibiotics for up to two years and endure often intolerable side effects.

.




  • Tags: Asia, Diseases, presentation, Tuberculosis, Uzbekistan
  • TB SYMPOSIUM - How to successfully adapt national TB Control Programmes, Veen_Jaap

    Based on a presentation prepared by Gunta Dravniece, Senior consultant, KNCV


  • Tags: Asia, Cambodia, Diseases, Tuberculosis, World TB Day
  • Improving TB care in Cambodia

    Cambodia has one of the highest tuberculosis burdens in the world.


  • Tags: Access Campaign, Diseases, Press Release, Tuberculosis, World TB Day
  • New TB test to detect more people who need DR-TB treatment

    WORLD TB DAY Press Release: A promising new diagnostic test will finally help detect more people with drug-resistant tuberculosis (DR-TB), increasing the urgency to solve major problems around the pricing and supply of DR-TB medicines, according to a new report by MSF.


  • Tags: Africa, Article, Diseases, Multi Media, Photo Gallery
  • World TB Day - Share in my solitude

    Living with drug-resistant TB. Photos by Krisanne Johnson.


  • Tags: Article, Asia, Diseases, Multi Media, Photo Gallery
  • World TB Day: A slow and painful process

    Photographer and MSF field worker Misha Friedman visited MSF’s TB project in Nukus, western Uzbekistan.


  • Tags: Access Campaign, Diseases, DNDi, Report, Tuberculosis
  • DR-TB drugs under the microscope

    Treating DR-TB is complicated from a programmatic perspective: treatment is individualised, tailored according to which drugs a patient is resistant to. It is long and taxing, requiring people to take a course of antibiotics for up to two years and endure often intolerable side effects.



Straker Translations